MIB-1 Index and Anal Carcinomas
Author Information
Author(s): AS Allal, L Alonso-Pentzke, S Remadi
Primary Institution: University Hospital of Geneva
Hypothesis
Does the MIB-1 index have prognostic value in anal carcinomas treated with radiotherapy?
Conclusion
The MIB-1 index does not predict the outcome of patients with anal carcinomas treated by radiotherapy with or without chemotherapy.
Supporting Evidence
- The median MIB-1 index was 53%, which is among the highest reported for cancers of epithelial origin.
- Patients with high vs low MIB-1 indices had similar outcomes in terms of survival and disease control.
- No significant association was found between MIB-1 indices and various clinicopathological parameters.
Takeaway
This study looked at whether a specific marker called the MIB-1 index could help predict how well patients with anal cancer would do after treatment, but it turned out it didn't help at all.
Methodology
The study analyzed the MIB-1 index in tissue samples from 55 patients with anal carcinoma treated with radiotherapy, using a modified immunoperoxidase technique.
Potential Biases
Potential sampling bias related to variations in the MIB-1 index throughout the tumor specimen.
Limitations
The study is retrospective and based on a small number of events, which may limit the reliability of the findings.
Participant Demographics
{"median_age":65,"gender_ratio":"15 males to 40 females"}
Statistical Information
P-Value
{"overall_survival":0.7,"locoregional_control":0.5,"disease_free_survival":0.5}
Confidence Interval
{"locoregional_control":"95% CI 60-85%","disease_free_survival":"95% CI 56-82%","overall_survival":"95% CI 54-81%"}
Want to read the original?
Access the complete publication on the publisher's website